AZTA Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -9.04% compared to Azenta's net margin of -728.57%. Azenta's return on equity of -7.97% beat Bionano Genomics's return on equity of -158.95%.

Azenta has a consensus price target of $51.60, signalling upside risk potential of 102.35%. On the other hand Bionano Genomics has an analysts' consensus of $7.00 which suggests that it could grow by 72.84%. Given that Azenta has higher upside potential than Bionano Genomics, analysts believe Azenta is more attractive than Bionano Genomics.

Azenta has a beta of 1.660, which suggesting that the stock is 66.003% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.086, suggesting its more volatile than the S&P 500 by 108.641%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $147.5M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Azenta's net income of -$13.3M is higher than Bionano Genomics's net income of -$44.2M. Notably, Azenta's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 1.98x versus 0.10x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -9.04% compared to Azenta's net margin of 1.4%. Azenta's return on equity of -7.97% beat Bruker's return on equity of 6.78%.

Azenta has a consensus price target of $51.60, signalling upside risk potential of 102.35%. On the other hand Bruker has an analysts' consensus of $62.05 which suggests that it could grow by 64.42%. Given that Azenta has higher upside potential than Bruker, analysts believe Azenta is more attractive than Bruker.

Azenta has a beta of 1.660, which suggesting that the stock is 66.003% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Azenta pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta quarterly revenues are $147.5M, which are smaller than Bruker quarterly revenues of $979.6M. Azenta's net income of -$13.3M is lower than Bruker's net income of $13.7M. Notably, Azenta's price-to-earnings ratio is -- while Bruker's PE ratio is 49.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 1.98x versus 1.68x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -9.04% compared to Azenta's net margin of 0.07%. Azenta's return on equity of -7.97% beat Harvard Bioscience's return on equity of -18.36%.

Azenta has a consensus price target of $51.60, signalling upside risk potential of 102.35%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1053.85%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

Azenta has a beta of 1.660, which suggesting that the stock is 66.003% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.794%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $147.5M, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Azenta's net income of -$13.3M is lower than Harvard Bioscience's net income of $18K. Notably, Azenta's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 1.98x versus 0.18x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Precipio has a net margin of -9.04% compared to Azenta's net margin of -12.02%. Azenta's return on equity of -7.97% beat Precipio's return on equity of -23.34%.

Azenta has a consensus price target of $51.60, signalling upside risk potential of 102.35%. On the other hand Precipio has an analysts' consensus of -- which suggests that it could grow by 244.83%. Given that Precipio has higher upside potential than Azenta, analysts believe Precipio is more attractive than Azenta.

Azenta has a beta of 1.660, which suggesting that the stock is 66.003% more volatile than S&P 500. In comparison Precipio has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.21%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Precipio pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $147.5M, which are larger than Precipio quarterly revenues of $5.2M. Azenta's net income of -$13.3M is lower than Precipio's net income of -$626K. Notably, Azenta's price-to-earnings ratio is -- while Precipio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 1.98x versus 0.44x for Precipio. Usually stocks with elevated PS ratios are considered overvalued.